Načítá se...
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk–benefit
Imagine a medicine that is expected to have very limited effects based upon knowledge of its pharmacology and (patho)physiology and that is studied in the wrong population, with low-quality studies that use a surrogate end-point that relates to the clinical end-point in a partial manner at most. Suc...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Science Inc
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3690100/ https://ncbi.nlm.nih.gov/pubmed/23216370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12034 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|